Humanigen Inc (OTCMKTS:HGEN) announced that two abstracts supporting the development of its hematological tumor-fighting program EphA3-CAR-T will be presented at the upcoming annual meeting of the Society for Neuro-Oncology in Phoenix.
EphA3-CAR-T is built on the backbone of ifabotuzumab, the company’s proprietary anti-EphA3 antibody drug, and the first abstract covers a Phase 1 study in patients with Glioblastoma multiforme, a rare brain cancer.
Preliminary results from eight patients showed that ifabotuzumab is effectively delivered across the blood-tumor barrier and accumulates specifically at the tumor site in all patients treated to date with no observed normal tissue uptake.
Humanigen shares rose 6.1% to $0.65 on Tuesday.
"Our results show that ifabotuzumab is safe and very effective at targeting the tumor,” said professors Hui Gan and Andrew Scott, who led the study from the Olivia Newton-John Cancer Research Institute in Melbourne. “We are also excited that there are early indications that ifabotuzumab may help to control disease growth in some patients."
EphA3 is a tumor-restricted antigen expressed in the tumor vasculature of aggressive brain cancers. It also surfaces in the tumor vasculature and tumor stroma of colon, lung, kidney and bladder tumors, as well as melanoma.
The second abstract details how a single chain variable region fragment of ifabotuzumab was used to develop an antigen receptor to be used in chimeric antigen receptor T cell (CAR-T) therapy.
Data from in vivo and combinatorial CAR-T experiments will be reported during an oral presentation on November 22.
"These results indicate for the first time that targeting EphA3 with CAR-T cells is feasible, efficacious, and represents a novel therapeutic strategy for solid tumors," CEO Cameron Durrant said in a statement. "Our EphA3-CAR-T program [is] another pillar in our developing cell therapy pipeline.”
“While we continue to develop our GM-CSF neutralization platform with [our clinical collaborator] Kite, we are also busy building next generation CAR-T therapies with our combinatorial GM-CSF gene-editing platform and our other CAR-T programs focused on novel tumor targets," Durrant added.
—Updated to include stock movement—
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel